Programme
The educational programme features sessions presented by each global society.
Please note all programme times are Greenwich Mean Time (GMT)
| TIME | PROGRAMME |
|---|---|
| 08.00 – 08.05 | WELCOME Robin Gore |
| 08.05 – 09.05 |  Japanese Society of Allergology |
| 08.05 – 08.20 | Allergen immunotherapy in asthma Discover how allergen immunotherapy, including SCIT and SLIT, can improve asthma control, modify disease, and offer long-term prevention in allergic conditions worldwide. Kazuyuki Nakagome |
| 08.20 – 08.35 | Advances in the diagnosis and treatment of Stevens–Johnson syndrome/toxic epidermal necrolysis Explore advances in diagnosing and treating SJS/TEN, including cancer drug reactions with similar features. Gain practical guidance and support global efforts to standardise care. Yuko Watanabe |
| 08.35 – 08.50 | Japanese guidelines for atopic dermatitis Sharing the Japanese guidelines for atopic dermatitis to highlight evidence-based treatment strategies and promote shared decision-making between physicians and patients, respecting individual values and preferences. Hidehisa Saeki |
| 08.50 – 09.05 | Panel Q&A |
| 09:05 – 09:20 | BREAK |
| 09.20 – 10.20 | COMPANY SYMPOSIUM Thermo Fisher Scientific |
| 10.20 – 11.20 |  Chaired by: Claudia Gore |
| 10.20 – 10.35 | Lessons learned on the standardisation of oral food challenges A practical session on oral food challenges, detailing how and when to perform them and how to avoid pitfalls in diagnosing and following up food allergy. Philippe Eigenmann |
| 10.35 – 10.50 | EAACI’s Strategic Vision: Artificial Intelligence as a Transformative Force in Allergic Disease Management – Clinical Applications and Mechanistic Insights Explore how AI can transform global allergy care by improving diagnosis, personalizing treatment, and expanding equitable access to specialist-level expertise in alignment with EAACI’s evidence-based vision for clinical implementation. Mo Shamji |
| 10.50 – 11.05 | EAACI strategy for the precise management of antibiotic allergy and its impact on EU antibiotic resistance The talk emphasises improving beta-lactam allergy diagnosis and de-labelling false cases to reduce antibiotic resistance and enhance global health outcomes. Maria Torres |
| 11.05 – 11.20 | Panel Q&A |
| 11.20 – 11.40 | BREAK |
| 11.40 – 13.00 | Presidents’ Forum This is the only worldwide platform where presidents of 5 global societies meet to discuss topics of interest in the field of allergic disease. It provides an opportunity to ask questions to the presidents Live meeting of the Presidents of the Partner Societies |
| 13.00 – 13.40 | BREAK |
| 13.40 – 14.40 | Company symposium |
| 14.40 – 15.40 |  Chaired by: Stephen Durham |
| 14.40 – 14.55 | Allergy Psychology interactive cases Explore how the mind shapes allergic reactions and learn about the link between immunology and psychology to deliver new treatment approaches that address both the physical and mental aspects of allergy. Christina Jones |
| 14.55 – 15.10 | Atopic interactive cases Presentation of a challenging adolescent atopic dermatitis case, highlighting therapeutic decision-making using latest guidelines, network meta-analyses, treat-to-target strategies, and immunological targets of emerging systemic therapies. Carsten Flohr |
| 15.10 – 15.25 | Venom allergy interactive cases From stings to systemic reactions – understand and manage hymenoptera venom allergy with confidence. Pamela Ewan |
| 15.25 – 15.40 | Panel Q&A |
| 15.40 – 15.55 | BREAK |
| 15.55 – 16.55 |  Chaired by: Shuaib Nasser |
| 15.55 – 16.10 | Food Protein-Induced Enterocolitis Syndrome (FPIES): Current Status and Future Directions Learn how to recognise, diagnose, and manage FPIES, and explore emerging research shaping safer food introduction and improved clinical care. Carina Venter |
| 16.10 – 16.25 | Pollen-Food Allergy Syndrome: Consensus on Management Explore the rising global prevalence of Pollen-Food Allergy Syndrome, its diverse presentations, potential environmental and dietary causes, and the current challenges in achieving consistent international diagnosis and management guidelines. Amanda Cox |
| 16.25 – 16.40 | Omalizumab Treatment of Food Allergy Understand the risks, benefits, and real-world impact of biologics in allergy care Aikaterini Anagnostou |
| 16.40 – 16.55 | Panel Q&A |
| 16.55 – 17.10 | BREAK |
| 17.10 – 18.10 |  Chaired by: Olympia Tsilochristou |
| 17.10 – 17.25 | DRESS syndrome: A literature review and treatment algorithm DRESS syndrome is a rare, serious drug-induced hypersensitivity reaction with up to 10% mortality. It affects multiple organs and often presents 2–8 weeks after drug exposure, delaying diagnosis. This session explores the nuances of DRESS syndrome treatment. Luz Fonacier |
| 17.25 – 17.40 | DRACMA’ guideline update 2024 – Milk supplement/replacement formulas for infants and toddlers with CMA A session exploring milk protein allergy in infancy, its persistence and severity, and the importance of a reasoned substitute choice when breastfeeding is not available. Alessandro Fiocchi |
| 17.40 – 17.55 | Standards for intravenous Rapid Drug Desensitisation Explore standardised intravenous rapid drug desensitisation protocols to harmonise practice, enhance patient safety, and equip clinicians with the knowledge and confidence to safely manage high-risk allergic patients worldwide. Ricardo Madrigal |
| 17.55 – 18.10 | Panel Q&A |
| 18.10 – 18.15 | CLOSING AND PRESIDENT’S REMARKS |
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AAAAI and the British Society for Allergy and Clinical Immunology. The AAAAI is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
The American Academy of Allergy, Asthma & Immunology designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.